Home Ingredients Microcrystalline Hydroxyapatite (MCHA / MCH)
Bone Health

Microcrystalline Hydroxyapatite (MCHA / MCH)

Evidence Level
Moderate
2 Clinical Trials
5 Documented Benefits
3/5 Evidence Score

Microcrystalline hydroxyapatite (MCHA, also called ossein-hydroxyapatite complex / OHC) is calcium derived from bovine bone — providing calcium and phosphorus and collagen-derived organic matrix in the same compound found in human bone. Some studies suggest superior bone-building effects vs calcium carbonate or citrate. More expensive; animal-derived (not vegetarian/vegan); quality varies significantly by source.

Studied Dose 1,000-2,000 mg MCHA/day (provides ~250-500 mg elemental calcium plus phosphorus and collagen peptides)
Active Compound Microcrystalline hydroxyapatite (Ca10(PO4)6(OH)2 + organic matrix)

Benefits

Bone-Identical Mineral Form

Hydroxyapatite (Ca10(PO4)6(OH)2) is the actual mineral structure of human bone and tooth enamel. MCHA provides calcium and phosphorus in the same crystalline form found in bone — proposed advantage for bone matrix incorporation.

Supported by Trial 1

Postmenopausal Bone Density (Some Evidence)

Several trials suggest MCHA produces equal-or-better BMD effects vs calcium carbonate or citrate in postmenopausal women. Castelo-Branco et al. trials and Pelayo et al. 2007 four-year follow-up support efficacy. Not consistently superior in head-to-head comparisons.

Supported by Trial 1, Trial 2

Phosphorus Content

MCHA provides phosphorus alongside calcium — bone needs both. Most calcium supplements lack phosphorus; MCHA's phosphorus content matches bone composition.

Supported by Trial 1

Organic Matrix Components

MCHA contains residual collagen-derived peptides, growth factors (theoretically), and trace elements from bone matrix — distinct from simple inorganic calcium salts.

Supported by Trial 1

Slow Calcium Release

Hydroxyapatite has lower acute solubility than calcium carbonate or citrate — leads to smaller transient calcium spikes. Some practitioners propose this is more physiological.

Supported by Trial 1

Mechanism of action

1

Hydroxyapatite Crystal Structure

Calcium phosphate crystallized as Ca10(PO4)6(OH)2 — the identical mineral structure of bone hydroxyapatite. Slowly dissolves in stomach to release Ca²⁺ and phosphate ions for absorption.

2

Phosphorus + Calcium Combined

Bone is ~99% hydroxyapatite (calcium phosphate) — providing both minerals together is theoretically more physiologic than calcium-only supplementation.

3

Slower Absorption

Lower acute solubility means slower calcium release vs carbonate/citrate — smaller serum calcium spikes; some practitioners consider this safer for cardiovascular concerns about calcium supplementation.

4

Bovine Bone Source Variability

MCHA quality varies significantly by source — bovine origin (concerns about BSE/prion contamination, pesticide exposure, antibiotic residues), processing methodology, and standardization. New Zealand-sourced MCHA is generally considered higher-quality.

Clinical trials

1
MCHA vs Calcium Citrate vs Carbonate

Clinical trial comparing acute and 3-month effects of MCHA, calcium citrate, and calcium carbonate on serum calcium and bone turnover markers in postmenopausal women.

Postmenopausal women.

MCHA produced smaller serum calcium AUC vs citrate/carbonate (slower absorption) but similar effect on bone turnover markers. PTH suppression less pronounced with MCHA — interpreted as more physiological pattern. Not directly superior on hard outcomes.

2
Ossein-Hydroxyapatite Complex 4-Year Follow-Up

Four-year follow-up of OHC supplementation for osteoporosis prevention in postmenopausal women.

Postmenopausal women.

MCHA/OHC supported BMD maintenance over 4 years. Industry-funded research; not direct comparison to bisphosphonates (which are gold-standard pharmacotherapy for osteoporosis).

Side effects and drug interactions

Common Potential side effects

Generally well-tolerated.
Larger pills (lower elemental calcium content per gram of MCHA).
Constipation — less than calcium carbonate but still possible.
Animal source concerns — BSE/prion (resolved with reputable sources), pesticide exposure, antibiotic residues.
Cost — substantially more expensive than carbonate or citrate.
Religious/dietary restrictions — bovine-derived; not vegetarian/vegan; may not be kosher/halal depending on source/processing.

Important Drug interactions

Same general calcium drug interactions — tetracyclines, quinolones, bisphosphonates, levothyroxine, iron; separate by 2-4 hours.
Phosphorus content — important for renal patients; CKD often requires phosphorus restriction; avoid MCHA in late-stage CKD.
Aluminum-containing drugs — separate.
Thiazide diuretics — hypercalcemia risk.

Featured in these supplement guides

Bone Density→Menopause Symptoms→

More Bone Health Ingredients

Bone Health
Calcium
Calcium is the most abundant mineral in the body — about 99% stored in bones and teeth, wi…
Bone Health
Vitamin D
Vitamin D is a fat-soluble vitamin and steroid hormone precursor essential for calcium abs…
Bone Health
Copper
Copper is an essential trace mineral and cofactor for over 30 enzymatic reactions, includi…
Bone Health
Ferrous Sulfate
Ferrous sulfate is the most common, cheapest, and longest-established oral iron form — rec…

Frequently asked questions about Microcrystalline Hydroxyapatite (MCHA / MCH)

What is microcrystalline hydroxyapatite (MCHA)?

MCHA is a whole-bone-derived calcium supplement that supplies calcium and phosphorus in the natural hydroxyapatite form, along with trace bone proteins and minerals. It is specifically marketed for bone density.

Is MCHA better than regular calcium for bones?

Some studies suggest microcrystalline hydroxyapatite may support bone density as well as or better than simple calcium salts, possibly due to its bone-matrix components. Evidence is mixed, but it is a well-regarded bone-support form.

How much MCHA should I take?

Use it to fill the gap to a 1,000 to 1,200 mg daily calcium total from all sources, in divided doses near 500 mg of elemental calcium each. Check the label for elemental calcium, since MCHA also supplies phosphorus.

Is MCHA safe?

It is generally well tolerated. Because it is derived from bovine bone, choose products from reputable, tested sources for purity. Pair it with vitamin D and avoid excessive total calcium intake.

What is Microcrystalline Hydroxyapatite?

Microcrystalline hydroxyapatite (MCHA, also called ossein-hydroxyapatite complex / OHC) is calcium derived from bovine bone — providing calcium and phosphorus and collagen-derived organic matrix in the same compound found in human bone.

What is Microcrystalline Hydroxyapatite used for?

Microcrystalline Hydroxyapatite is researched primarily for Bone Health. Hydroxyapatite (Ca10(PO4)6(OH)2) is the actual mineral structure of human bone and tooth enamel. MCHA provides calcium and phosphorus in the same crystalline form found in bone — proposed advantage for bone matrix incorporation.

What is the recommended dosage of Microcrystalline Hydroxyapatite?

The clinically studied dose is 1,000-2,000 mg MCHA/day (provides ~250-500 mg elemental calcium plus phosphorus and collagen peptides) Always follow the product label and check with a healthcare provider for personal advice.

Is Microcrystalline Hydroxyapatite safe, and does it have side effects?

For most healthy adults, Microcrystalline Hydroxyapatite is well tolerated at studied doses. Reported effects can include: Generally well-tolerated. Larger pills (lower elemental calcium content per gram of MCHA). It may also interact with some medications. Microcrystalline Hydroxyapatite is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does Microcrystalline Hydroxyapatite interact with any medications?

Possible interactions include: Same general calcium drug interactions — tetracyclines, quinolones, bisphosphonates, levothyroxine, iron; separate by 2-4 hours. Phosphorus content — important for renal patients; CKD often requires phosphorus restriction; avoid MCHA in late-stage CKD. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for Microcrystalline Hydroxyapatite?

NutraSmarts rates the evidence for Microcrystalline Hydroxyapatite as Moderate (3 out of 5). It is backed by 2 clinical trials and 1 cited reference summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(1 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Bristow SM, Gamble GD, Stewart A, et al. Acute and 3-month effects of microcrystalline hydroxyapatite, calcium citrate and calcium carbonate on serum calcium and markers of bone turnover: a randomised controlled trial in postmenopausal women. Br J Nutr. 2014;112(10):1611-20..PubMedUsed to support: Randomized trial of microcrystalline hydroxyapatite on serum calcium and bone-turnover markers in postmenopausal women.